[go: up one dir, main page]

WO2003084566A3 - Proteins involved in the regulation of energy homeostasis - Google Patents

Proteins involved in the regulation of energy homeostasis Download PDF

Info

Publication number
WO2003084566A3
WO2003084566A3 PCT/EP2003/003747 EP0303747W WO03084566A3 WO 2003084566 A3 WO2003084566 A3 WO 2003084566A3 EP 0303747 W EP0303747 W EP 0303747W WO 03084566 A3 WO03084566 A3 WO 03084566A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulation
energy homeostasis
proteins involved
energy
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/003747
Other languages
French (fr)
Other versions
WO2003084566A2 (en
Inventor
Karsten Eulenberg
Thomas Haeder
Arnd Steuernagel
Guenter Broenner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Develogen AG
Original Assignee
Develogen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen AG filed Critical Develogen AG
Priority to AU2003224062A priority Critical patent/AU2003224062A1/en
Publication of WO2003084566A2 publication Critical patent/WO2003084566A2/en
Publication of WO2003084566A3 publication Critical patent/WO2003084566A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/60—New or modified breeds of invertebrates
    • A01K67/61—Genetically modified invertebrates, e.g. transgenic or polyploid
    • A01K67/65—Genetically modified arthropods
    • A01K67/68—Genetically modified insects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)

Abstract

The present invention discloses novel uses for energy homeostasis regulating proteins and polynucleotides encoding these in the diagnosis, study, prevention, and treatment of metabolic diseases and disorders.
PCT/EP2003/003747 2002-04-10 2003-04-10 Proteins involved in the regulation of energy homeostasis Ceased WO2003084566A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003224062A AU2003224062A1 (en) 2002-04-10 2003-04-10 Proteins involved in the regulation of energy homeostasis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP02008037.0 2002-04-10
EP02008037 2002-04-10
EP02008509.8 2002-04-15
EP02008509 2002-04-15
EP02009068 2002-04-23
EP02009068.4 2002-04-23

Publications (2)

Publication Number Publication Date
WO2003084566A2 WO2003084566A2 (en) 2003-10-16
WO2003084566A3 true WO2003084566A3 (en) 2004-04-01

Family

ID=28794670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/003747 Ceased WO2003084566A2 (en) 2002-04-10 2003-04-10 Proteins involved in the regulation of energy homeostasis

Country Status (2)

Country Link
AU (1) AU2003224062A1 (en)
WO (1) WO2003084566A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023100A2 (en) * 1998-10-22 2000-04-27 Curagen Corporation Genes and proteins predictive and therapeutic for renal disease and associated disorders
WO2002005810A1 (en) * 2000-07-18 2002-01-24 Joslin Diabetes Center Modulation of nitric oxide synthase by pkc

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023100A2 (en) * 1998-10-22 2000-04-27 Curagen Corporation Genes and proteins predictive and therapeutic for renal disease and associated disorders
WO2002005810A1 (en) * 2000-07-18 2002-01-24 Joslin Diabetes Center Modulation of nitric oxide synthase by pkc

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KUEBLER D ET AL: "Genetic suppression of seizure susceptibility in Drosophila", JOURNAL OF NEUROPHYSIOLOGY 2001 UNITED STATES, vol. 86, no. 3, 2001, pages 1211 - 1225, XP002248167, ISSN: 0022-3077 *
SCHOMBERG L ET AL: "Human TRH-degrading ectoenzyme, cDNA cloning, functional expression, genomic structure and chromosomal assignment", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 265, 1999, pages 415 - 422, XP002199510, ISSN: 0014-2956 *

Also Published As

Publication number Publication date
AU2003224062A1 (en) 2003-10-20
WO2003084566A2 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2004009034A3 (en) Thiomolybdate analogues and uses thereof
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
WO2002076494A3 (en) USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
WO2003063796A3 (en) Heterocyclic arylsulfonamidobenzylic compounds
PL378360A1 (en) Use of intraputaminal infused glial cell-line derived neurotrophic factor in the treatment of parkinson's disease in humans
WO2004032864A3 (en) X-nitro compounds, pharmaceutical compositions thereof and uses therof
WO2004035082A3 (en) Proteins involved in the regulation of energy homeostasis
WO2003092715A3 (en) Proteins involved in the regulation of energy homeostasis
WO2004020465A3 (en) Proteins involved in the regulation of energy homeostasis
WO2004047855A3 (en) Proteins involved in the regulation of energy homeostasis
WO2004016641A3 (en) Proteins involved in the regulation of energy homeostasis
WO2004054601A3 (en) Fwd, pp2c1, adk3, cg3860, cdk4, cg7134, eip75b involved in the regulation of energy homeostasis
WO2004064856A3 (en) Proteins involved in the regulation of energy homeostasis
WO2003084566A3 (en) Proteins involved in the regulation of energy homeostasis
WO2004002513A3 (en) Proteins involved in the regulation of energy homeostasis
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2003066086A3 (en) Proteins involved in the regulation of energy homeostatis
WO2003026566A3 (en) Atlastin
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2005025590A3 (en) Use of a dg280 protein product for preventing and treating metabolic disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP